A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs

• ClinicalTrials.gov Identifier: NCT02308163
• Recruitment Status: Completed
• First Posted: December 4, 2014
• Results First Posted: March 16, 2020
• Last Update Posted: March 16, 2020
• Sponsor: Astellas Pharma Inc
• Information provided by (Responsible Party): Astellas Pharma Inc

Study Description

Brief Summary:

The objective of this study was to verify the superiority of ASP015K alone or in combination with disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who had an inadequate response to DMARDs

Condition or disease	Intervention/treatment	Phase
Rheumatoid Arthritis	Drug: Peficitinib; Drug: Placebo; Biological: Etanercept	Phase 3

Detailed Description:

This was a multi-center, randomized, placebo-controlled, double-blind, parallel-group, confirmatory study to evaluate the efficacy and safety of ASP015K alone or in combination with DMARDs in participants with RA who had an inadequate response to DMARDs.

Etanercept was also administered as the reference drug in an open-label manner. The study drug was orally administered once daily (QD) after breakfast for 52 weeks. Etanercept was administered subcutaneously QD for 52 weeks. At Week 12, participants in the placebo group were switched to ASP015K.

The dose of ASP015K to be started at Week 12 for the placebo group was determined randomly at baseline in advance and switched in a blinded manner.

Participants in ASP015K group or placebo groups who had completed the study were eligible for participation in an open-label extension study (015K-CL-RAJ2).

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 509 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs
• Actual Study Start Date: August 8, 2014
• Actual Primary Completion Date: January 23, 2017
• Actual Study Completion Date: November 22, 2017

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Placebo; Participants were assigned to receive placebo to peficitinib once a day until week 12.	Drug: Placebo; oral
Experimental: Peficitinib 100 mg; Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.	Drug: Peficitinib; oral; Other Name: ASP015K
Experimental: Peficitinib 150 mg; Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.	Drug: Peficitinib; oral; Other Name: ASP015K
Active Comparator: Etanercept; Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.	Biological: Etanercept; subcutaneous injection

Outcome Measures

Primary Outcome Measures :

1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) C-Reactive Protein (CRP) Response at Week 12 [ Time Frame: Baseline and Week 12/early termination (ET) ]

   The ACR20 response required that all criteria from (1) to (3) below be met.

   1. Tender joint count (TJC) : ≥ 20% reduction compared with baseline.
   2. Swollen joint count (SJC) : ≥ 20% reduction compared with baseline.
   3. ≥ 20% improvement in 3 or more of the following 5 parameters compared with baseline

   (3) ≥ 20% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, Subject's Global Assessment of Arthritis (SGA), Physician's Global Assessment of Arthritis (PGA), Health Assessment Questionnaire - Disability Index (HAQ-DI), C-Reactive Protein (CRP).

Secondary Outcome Measures :

1. Percentage of Participants With an ACR20-CRP Response Through Week 52 [ Time Frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]

   The ACR20 response required that all criteria from (1) to (3) below be met.

   1. TJC : ≥ 20% reduction compared with baseline.
   2. SJC : ≥ 20% reduction compared with baseline.
   3. ≥ 20% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.
2. Percentage of Participants With an American College of Rheumatology 50% (ACR50)-CRP Response at Week 12 [ Time Frame: Baseline and Week 12/ET ]

   The ACR50 response required that all criteria from (1) to (3) below be met.

   1. TJC : ≥ 50% reduction compared with baseline.
   2. SJC : ≥ 50% reduction compared with baseline.
   3. ≥ 50% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.
3. Percentage of Participants With an ACR50-CRP Response Through Week 52 [ Time Frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]

   The ACR50 response required that all criteria from (1) to (3) below be met.

   1. TJC : ≥ 50% reduction compared with baseline.
   2. SJC : ≥ 50% reduction compared with baseline.
   3. ≥ 50% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.
4. Percentage of Participants With an American College of Rheumatology 70% (ACR70)-CRP Response at Week 12 [ Time Frame: Baseline and Week 12/ET ]

   The ACR70 response required that all criteria from (1) to (3) below be met.

   1. TJC : ≥ 70% reduction compared with baseline.
   2. SJC : ≥ 70% reduction compared with baseline.
   3. ≥ 70% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.
5. Percentage of Participants With an ACR70-CRP Response Through Week 52 [ Time Frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]

   The ACR70 response required that all criteria from (1) to (3) below be met.

   1. TJC : ≥ 70% reduction compared with baseline.
   2. SJC : ≥ 70% reduction compared with baseline.
   3. ≥ 70% improvement in 3 or more of the following 5 parameters compared with baseline: Subject's assessment of pain, SGA, PGA, HAQ-DI, CRP.
6. Change From Baseline in Disease Activity Score (DAS) 28-CRP at Week 12 [ Time Frame: Baseline and Week 12/ET ]

   DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.

   DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity.

7. Change From Baseline DAS28-CRP Through Week 52 [ Time Frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]
   DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description. DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. Higher DAS28 score indicated greater disease activity.
8. Change From Baseline in DAS28-Erythrocyte Sedimentation Rate (ESR) at Week 12 [ Time Frame: Baseline and Week 12/ET ]

   DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.

   DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity.

9. Change From Baseline in DAS28-ESR Through Week 52 [ Time Frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]

   DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.

   DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. Higher DAS28 score indicated greater disease activity.

10. Change From Baseline in TJC (68 Joints) at Week 12 [ Time Frame: Baseline and Week 12/ET ]

    The following 68 joints subjects to assessment were examined for tender joints and the location was confirmed. Higher TJC68 indicated greater disease activity.

    Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), hip joints (2), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).

11. Change From Baseline in TJC (68 Joints) Through Week 52 [ Time Frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]

    The following 68 joints subjects to assessment were examined for tender joints and the location was confirmed. Higher TJC68 indicated greater disease activity.

    Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), hip joints (2), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).

12. Change From Baseline in Swollen Joint Count (SJC) (66 Joints) at Week 12 [ Time Frame: Baseline and Week 12/ET ]

    The following 66 joints subjects to assessment were examined for swollen joints and the location was confirmed. Higher SJC66 indicated greater disease activity.

    Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).

13. Change From Baseline in SJC (66 Joints) Through Week 52 [ Time Frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]

    The following 66 joints subjects to assessment were examined for swollen joints and the location was confirmed. Higher SJC66 indicated greater disease activity.

    Temporomandibular joints (2), sternoclavicular joints (2), acromioclavicular joints (2), shoulder joints (2), elbow joints (2), wrist joints (2), distal interphalangeal joints (8), proximal interphalangeal joints of both hands (10), metacarpophalangeal joints (10), knee joints (2), ankle joints (2), tarsal bones (2), metatarsophalangeal joints (10), interphalangeal joint joints of toes (2), proximal interphalangeal joints of both feet (8).

14. Percentage of Participants Achieving DAS28-CRP < 2.6 at Week 12 [ Time Frame: Baseline and Week 12/ET ]

    DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.

    DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.

15. Percentage of Participants Achieving DAS28-CRP < 2.6 Through Week 52 [ Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]

    DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.

    DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.

16. Percentage of Participants Achieving DAS28-ESR < 2.6 at Week 12 [ Time Frame: Week 12/ET ]

    DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.

    DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.

17. Percentage of Participants Achieving DAS28-ESR < 2.6 Through Week 52 [ Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]

    DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.

    DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. If the DAS28 score was less than 2.6, the participant was considered to be in DAS28 remission.

18. Percentage of Participants Achieving DAS28-CRP <= 3.2 at Week 12 [ Time Frame: Week 12/ET ]

    DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.

    DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.

19. Percentage of Participants Achieving DAS28-CRP <= 3.2 Through Week 52 [ Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]

    DAS28-CRP response consisted of following parameters: TJC (28 joints), SJC (28 joints), CRP, SGA, and calculated according to below description.

    DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.36 ln (CRP + 1) + 0.014 × SGA + 0.96. DAS28-CRP scores range from 0.96 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.

20. Percentage of Participants Achieving DAS28-ESR <= 3.2 at Week 12 [ Time Frame: Week 12/ET ]

    DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.

    DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.

21. Percentage of Participants Achieving DAS28-ESR <= 3.2 Through Week 52 [ Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]

    DAS28-ESR response consisted of following parameters: TJC (28 joints), SJC (28 joints), ESR, SGA , and calculated according to below description.

    DAS28 = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 × SGA. DAS28-ESR scores range from 0 to approximately 10. DAS28 score of less than or equal to 3.2 was considered to be low disease activity.

22. Change From Baseline in CRP at Week 12 [ Time Frame: Baseline and Week 12/ET ]
    Higher CRP indicates greater disease activity.
23. Change From Baseline in CRP Through Week 52 [ Time Frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]
    Higher CRP indicates greater disease activity.
24. Change From Baseline in ESR at Week 12 [ Time Frame: Baseline and Week 12/ET ]
    Higher ESR indicates greater disease activity.
25. Change From Baseline in ESR Through Week 52 [ Time Frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]
    Higher ESR indicates greater disease activity.
26. Percentage of Participants With a European League Against Rheumatism (EULAR) Good Response Using DAS28-CRP at Week 12 [ Time Frame: Week 12/ET ]
    Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline > 1.2.
27. Percentage of Participants With a EULAR Good Response Using DAS28-CRP Through Week 52 [ Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]
    Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline > 1.2.
28. Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-CRP at Week 12 [ Time Frame: Week 12/ET ]
    Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline > 0.6, or DAS28 after treatment > 5.1 and improvement from baseline > 1.2.
29. Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-CRP Through Week 52 [ Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]
    Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline > 0.6, or DAS28 after treatment > 5.1 and improvement from baseline > 1.2.
30. Percentage of Participants With a Good EULAR Response Using DAS28-ESR at Week 12 [ Time Frame: Week 12/ET ]
    Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline > 1.2.
31. Percentage of Participants With a Good EULAR Response Using DAS28-ESR Through Week 52 [ Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]
    Good response was defined as DAS28 after treatment ≤ 3.2 and improvement from baseline > 1.2.
32. Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-ESR at Week 12 [ Time Frame: Week 12/ET ]
    Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline > 0.6, or DAS28 after treatment > 5.1 and improvement from baseline > 1.2.
33. Percentage of Participants With a Good or Moderate EULAR Response Using DAS28-ESR Through Week 52 [ Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]
    Good and moderate response was defined as DAS28 after treatment ≤ 5.1 and improvement from baseline > 0.6, or DAS28 after treatment > 5.1 and improvement from baseline > 1.2.
34. Percentage of Participants Achieving ACR / EULAR Remission at Week 12 [ Time Frame: Week 12/ET ]

    ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤ 1, CRP ≤ 1 mg/dL, and subject's global assessment of arthritis ≤ 1 cm (on a visual analog scale (VAS) of 0 - 100 mm).

    Statistical analysis of treatment difference vs placebo was not estimable for either peficitinib 100 mg or peficitinib 150 mg reporting groups.

35. Percentage of Participants Achieving ACR / EULAR Remission Through Week 52 [ Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]
    ACR/EULAR Remission was defined as TJC (68 joints) ≤ 1, SJC (66 joints) ≤ 1, CRP ≤ 1 mg/dL, and subject's global assessment of arthritis ≤ 1 cm (on a VAS of 0 - 100 mm).
36. Percentage of Participants Achieving Simplified Disease Activity Index (SDAI) Remission at Week 12 [ Time Frame: Week 12/ET ]

    SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description.

    SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3.

    Statistical analysis of treatment difference vs placebo was not estimable for either peficitinib 100 mg or peficitinib 150 mg reporting groups.

37. Percentage of Participants Achieving SDAI Remission Through Week 52 [ Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]

    SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description.

    SDAI = TJC + SJC + SGA + PGA + CRP. SDAI Remission was defined as SDAI score ≤ 3.3.

38. Change From Baseline in SDAI Score at Week 12 [ Time Frame: Baseline and Week 12/ET ]

    SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description.

    SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity.

39. Change From Baseline in SDAI Score Through Week 52 [ Time Frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]

    SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, CRP (mg/dL), and calculated according to below description.

    SDAI = TJC + SJC + SGA + PGA + CRP. The SDAI score ranges from 0 to approximately 86. Higher SDAI indicates greater disease activity.

40. Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Score <= 2.8 at Week 12 [ Time Frame: Week 12/ET ]

    CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description.

    CDAI = TJC + SJC + SGA + PGA. CDAI. Remission was defined as CDAI score ≤ 2.8. Statistical analysis of treatment difference vs placebo was not estimable for either peficitinib 100 mg or peficitinib 150 mg reporting groups.

41. Percentage of Participants Achieving CDAI Score <= 2.8 Through Week 52 [ Time Frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]

    CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description.

    CDAI = TJC + SJC + SGA + PGA. CDAI. Remission was defined as CDAI score ≤ 2.8.

42. Change From Baseline in CDAI Score at Week 12 [ Time Frame: Baseline and Week 12/ET ]

    CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description.

    CDAI = TJC + SJC + SGA + PGA. The CDAI score ranges from 0 to approximately 76. Higher CDAI indicates greater disease activity.

43. Change From Baseline in CDAI Score Through Week 52 [ Time Frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]

    CDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA, PGA, and calculated according to below description.

    CDAI = TJC + SJC + SGA + PGA. The CDAI score ranges from 0 to approximately 76. Higher CDAI indicates greater disease activity.

44. Change From Baseline in Physician's Global Assessment of Arthritis (PGA) at Week 12 [ Time Frame: Baseline and Week 12/ET ]
    The investigator assessed the participants' disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment.
45. Change From Baseline in PGA Through Week 52 [ Time Frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]
    The investigator assessed the participants' disease activity on a VAS of 0-100 mm on the physician assessment table. Higher PGA (100 mm VAS) scores indicate greater activity impairment.
46. Change From Baseline in Subject's SGA at Week 12 [ Time Frame: Baseline and Week 12/ET ]
    The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment.
47. Change From Baseline in SGA Through Week 52 [ Time Frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]
    The participant assessed his/her own disease activity on a VAS of 0-100 mm on the questionnaire form. Higher SGA (100 mm VAS) scores indicate greater activity impairment.
48. Change From Baseline in Subject's Assessment of Pain at Week 12 [ Time Frame: Baseline and Week 12/ET ]
    The participant assessed his/her own pain severity on a VAS from 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicate greater activity pain.
49. Change From Baseline in Subject's Assessment of Pain Through Week 52 [ Time Frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]
    The participant assessed his/her own pain severity on a VAS from 0-100 mm on the questionnaire form. Higher SGA of pain (100 mm VAS) scores indicate greater activity pain.
50. Number of Participants Who Withdrew Due to Lack of Efficacy [ Time Frame: Up to week 12 ]
    The number of participants who withdrew due to lack of efficacy up to week 12 was calculated.
51. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12 [ Time Frame: Baseline and Week 12/ET ]
    The HAQ-DI (range 0 - 3) was composed of 20 items in 8 categories (Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities). Each category has at least two questions. Within each category, participants reported the amount of difficulty they have in performing the specific question items. Higher HAQ-DI score indicates greater disease activity.
52. Change From Baseline in HAQ-DI Through Week 52 [ Time Frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 ]
    The HAQ-DI (range 0 - 3) was composed of 20 items in 8 categories (Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities). Each category has at least two questions. Within each category, participants reported the amount of difficulty they have in performing the specific question items. Higher HAQ-DI score indicates greater disease activity.
53. Change From Baseline in Short Form Health Survey - 36 Questions, Version 2 (SF-36v2) Physical Component Summary Score at Week 12 [ Time Frame: Baseline and Week 12/ET ]
    The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.
54. Change From Baseline in SF-36v2 Physical Component Summary Score Through Week 52 [ Time Frame: Baseline and Week 4, 8, 12, 28, and 52 ]
    The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.
55. Change From Baseline in SF-36v2 Mental Component Summary Score at Week 12 [ Time Frame: Baseline and Week 12/ET ]
    The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.
56. Change From Baseline in SF-36v2 Mental Component Summary Score Through Week 52 [ Time Frame: Baseline and Week 4, 8, 12, 28, and 52 ]
    The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.
57. Change From Baseline in SF-36v2 Role/Social Component Summary Score at Week 12 [ Time Frame: Baseline and Week 12/ET ]
    The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.
58. Change From Baseline in SF-36v2 Role/Social Component Summary Score Through Week 52 [ Time Frame: Baseline and Week 4, 8, 12, 28, and 52 ]
    The SF-36v2 was scored for the 8 subscales (each range: 0-100 scale): 1. physical functioning, 2. role physical, 3. bodily pain, 4. general health, 5. vitality, 6. social functioning, 7. role-emotional, and 8. mental health. Physical Component Summary Score, Mental Component Summary Score and Roll/Social Component Summary Score were calculated based on the 2007 General Japanese Population Means and Standard Deviations and coefficient. Component summary measures had means of 50 in 2007 General Japanese Population and deviation was expressed by the scale of 10. Higher score indicated better health state.
59. Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Percent Work Time Missed at Week 12 [ Time Frame: Baseline and Week 12/ET ]
    WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent work time missed due to problem: Q2/(Q2+Q4).
60. Change From Baseline in WPAI Percent Work Time Missed Through Week 52 [ Time Frame: Baseline and Week 4, 8, 12, 28, and 52 ]
    WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent work time missed due to problem: Q2/(Q2+Q4).
61. Change From Baseline in WPAI Percent Impairment While Working at Week 12 [ Time Frame: Baseline and Week 12/ET ]
    WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent impairment while working due to problem: Q5/10.
62. Change From Baseline in WPAI Percent Impairment While Working Through Week 52 [ Time Frame: Baseline and Week 4, 8, 12, 28, and 52 ]
    WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent impairment while working due to problem: Q5/10.
63. Change From Baseline in Percent Overall Work Impairment at Week 12 [ Time Frame: Baseline and Week 12/ET ]
    WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent overall work impairment due to problem: Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)].
64. Change From Baseline in WPAI Percent Overall Work Impairment Through Week 52 [ Time Frame: Baseline and Week 4, 8, 12, 28, and 52 ]
    WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent overall work impairment due to problem: Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4))x(Q5/10)].
65. Change From Baseline in WPAI Percent Activity Impairment at Week 12 [ Time Frame: Baseline and Week 12/ET ]
    WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent activity impairment due to problem: Q6/10.
66. Change From Baseline in WPAI Percent Activity Impairment Through Week 52 [ Time Frame: Baseline and Week 4, 8, 12, 28, and 52 ]
    WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the rheumatoid arthritis; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the rheumatoid arthritis on productivity while working; Q6=Impact of the rheumatoid arthritis on productivity while doing regular daily activities other than work) and a 1-week recall period. Higher WPAI scores indicate greater activity impairment. Multiply scores by 100 to express in percentages. Percent activity impairment due to problem: Q6/10.
67. Number of Participants With Adverse Events During the First 12 Weeks [ Time Frame: Week 0 to Week 12 ]
    Treatment-emergent adverse events (TEAEs) were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by System Organ Class (SOC) and Preferred Term (PT). Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE.
68. Number of Participants With Adverse Events From Week 12 [ Time Frame: Week 12 to week 52, plus 28 days after the week 52 visit for participants who did not enroll in the extension study ]
    Treatment-emergent adverse events (TEAEs) were defined as any AE that started or worsened in severity after initial dose of study drug or reference drug through week 52 or withdrawal. TEAEs were summarized using MedDRA (Version 11.1) by SOC and PT. Participants reporting more than 1 AE for a given MedDRA PT were counted only once for that term. Participants reporting more than 1 AE within a SOC were counted only once for the SOC total. Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade: grade 3 = severe or medically significant, grade 4 = life threatening, grade 5 = death related to AE.

Eligibility Criteria

• Ages Eligible for Study: 20 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Subject has RA diagnosed according to the 1987 American College of Rheumatology (ACR) criteria or the 2010 American College of Rheumatology/European League against Rheumatism (ACR/EULAR) criteria

• Subject who did not receive the following drugs, or received the drugs with stable dosage for at least 28 days prior to the baseline (start of treatment) for RA treatment:

  • Non-steroidal anti-inflammatory drugs (NSAIDs; excluding topical formulations), oral morphine or equivalent opioid analgesics (≤ 30 mg/day), acetaminophen, or oral corticosteroids (≤ 10 mg/day in prednisolone equivalent)

• At screening subject has active RA as evidenced by both of the following:

  • ≥ 6 tender/painful joints (using 68-joint assessment)
  • ≥ 6 swollen joints (using 66-joint assessment)
• CRP > 0.50 mg/dL at screening
• Subject meets the ACR 1991 Revised Criteria for the Classification of Global Functional Status in RA Class I, II or, III at screening.
• Inadequate responder to (including subjects who were intolerant of) at least one DMARD administered for at least 90 days prior to screening

Exclusion Criteria:

• Subject has received a biologic DMARD within the specified period
• Subject has received etanercept
• Inadequate responder to at least 3 biologic DMARDs as determined by investigator/sub-investigator
• Subject has received intra-articular, intravenous, intramuscular or endorectal (excluding suppositories for anal diseases) corticosteroid within 28 days prior to baseline
• Subject has participated in any study of ASP015K and has received ASP015K or placebo
• Subject has received other investigational drugs within 90 days or within 5 half-lives, whichever is longer, prior to baseline
• Subject has received plasma exchange therapy within 60 days prior to baseline
• Subject has undergone joint drainage, has received local anesthesia and nerve block, or has received articular cartilage protectant at the assessed joint within 28 days prior to baseline
• Subject has undergone surgery and has residual effects in the assessed joints at the discretion of investigator/sub-investigator, or is scheduled to undergo surgery that may affect the study evaluation of the assessed joints at the discretion of investigator/sub-investigator
• A diagnosis of inflammatory arthritis (psoriatic arthritis, ankylosing spondylitis, SLE, sarcoidosis, etc.) other than RA

• Any of the following laboratory values at screening:

  • Hemoglobin < 9.0 g/dL
  • Absolute neutrophil count < 1000/μL
  • Absolute lymphocyte count < 800/μL
  • Platelet count < 75000/μL
  • ALT ≥ 2 ×ULN
  • AST ≥ 2 × ULN
  • Total bilirubin (TBL) ≥ 1.5 × ULN
  • Estimated GFR ≤ 40 mL/min as measured by the MDRD method
  • β-D-glucan > ULN [in case of Japan: ≥ 11 pg/mL]
  • Positive HBs antigen, HBc antibody, HBs antibody or HBV-DNA quantitation (However, subject with negative HBs antigen and HBV-DNA quantitation, and positive HBc antibody and/or HBs antibody is eligible if HBV-DNA is monitored by HBV-DNA quantitation at every scheduled visit after initiation of study drug or reference drug administration.)
  • Positive HCV antibody
• Subject has a history of or concurrent active tuberculosis (TB)
• Subject has a history of or concurrent interstitial pneumonia and investigator/sub-investigator judges that it is inappropriate for the subject to participate in this study
• Subject has a history of or concurrent malignant tumor (except for successfully treated basal cell carcinoma)
• Subject has received live or live attenuated virus vaccination within 56 days prior to baseline. (Inactivated vaccines including influenza and pneumococcal vaccines are allowed.)
• Subject has a history of or concurrent demyelinating disorders
• Subject has any ongoing severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, neurological, infectious, or autoimmune disease except for RA (excluding Sjogren's syndrome and chronic thyroiditis), or any ongoing illness which would make the subject unsuitable for the study as determined by the investigator/sub-investigator
• Subject has a history of clinically significant allergy. (Clinically significant allergy includes allergies such as systemic urticaria induced by specific antigens and drugs, anaphylaxis, and allergy associated with shock necessitating hospitalized treatment.)
• Subject has concurrent cardiac failure, defined as NYHA classification Class III or higher, or a history of it
• Subject has concurrent prolonged QT syndrome or a history of it. Subject has prolonged QT interval (defined as QTc ≥ 500 msec. Subject has QTc ≥ 500 msec at retest will be excluded) at screening
• Subject has a history of positive HIV infection
• Subject has congenital short QT syndrome or a history of it. Subject has shortened QT interval (defined as QTc < 330 msec. Subject has QTc < 330 msec at retest will be excluded) at screening.

Contacts and Locations

Locations

Japan

JP00037

Nagoya, Aichi, Japan

JP00109

Nagoya, Aichi, Japan

JP00130

Nagoya, Aichi, Japan

JP00066

Okazaki, Aichi, Japan

JP00140

Toyoake, Aichi, Japan

JP00108

Toyohashi, Aichi, Japan

JP00156

Toyota, Aichi, Japan

JP00068

Yatomi, Aichi, Japan

JP00102

Kamagaya, Chiba, Japan

JP00127

Matsudo, Chiba, Japan

JP00115

Narashino, Chiba, Japan

JP00138

Yotsukaido, Chiba, Japan

JP00120

Iizuka, Fukuoka, Japan

JP00040

Kitakyushu, Fukuoka, Japan

JP00119

Kitakyushu, Fukuoka, Japan

JP00071

Kurume, Fukuoka, Japan

JP00097

Kurume, Fukuoka, Japan

JP00106

Kurume, Fukuoka, Japan

JP00033

Takasaki, Gunma, Japan

JP00026

Asahikawa, Hokkaido, Japan

JP00090

Hakodate, Hokkaido, Japan

JP00125

Kushiro, Hokkaido, Japan

JP00001

Sapporo, Hokkaido, Japan

JP00002

Sapporo, Hokkaido, Japan

JP00003

Sapporo, Hokkaido, Japan

JP00031

Sapporo, Hokkaido, Japan

JP00038

Sapporo, Hokkaido, Japan

JP00114

Sapporo, Hokkaido, Japan

JP00158

Sapporo, Hokkaido, Japan

JP00056

Akashi, Hyogo, Japan

JP00069

Himeji, Hyogo, Japan

JP00113

Kakogawa, Hyogo, Japan

JP00041

Kato, Hyogo, Japan

JP00042

Kobe, Hyogo, Japan

JP00092

Kobe, Hyogo, Japan

JP00154

Kobe, Hyogo, Japan

JP00117

Nishinomiya, Hyogo, Japan

JP00107

Hitachi, Ibaraki, Japan

JP00073

Koga, Ibaraki, Japan

JP00054

Mito, Ibaraki, Japan

JP00049

Morioka, Iwate, Japan

JP00084

Isehara, Kanagawa, Japan

JP00048

Kawasaki, Kanagawa, Japan

JP00058

Kawasaki, Kanagawa, Japan

JP00141

Sagamihara, Kanagawa, Japan

JP00096

Yokohama, Kanagawa, Japan

JP00128

Yokosuka, Kanagawa, Japan

JP00057

Tamana, Kumamoto, Japan

JP00004

Sendai, Miyagi, Japan

JP00027

Sendai, Miyagi, Japan

JP00036

Sendai, Miyagi, Japan

JP00105

Sendai, Miyagi, Japan

JP00151

Sendai, Miyagi, Japan

JP00050

Hyuga, Miyazaki, Japan

JP00162

Isehaya, Nagasaki, Japan

JP00101

Omura, Nagasaki, Japan

JP00103

Omura, Nagasaki, Japan

JP00153

Sasebo, Nagasaki, Japan

JP00094

Kashihara, Nara, Japan

JP00025

Nagaoka, Niigata, Japan

JP00144

Shibata, Niigata, Japan

JP00064

Beppu, Oita, Japan

JP00051

Setouchi, Okayama, Japan

JP00011

Hannan, Osaka, Japan

JP00134

Higashiosaka, Osaka, Japan

JP00078

Kawachinagano, Osaka, Japan

JP00137

Sakai, Osaka, Japan

JP00070

Suita, Osaka, Japan

JP00086

Suita, Osaka, Japan

JP00061

Toyonaka, Osaka, Japan

JP00075

Ureshino, Saga, Japan

JP00126

Gyoda, Saitama, Japan

JP00007

Hiki, Saitama, Japan

JP00082

Iruma, Saitama, Japan

JP00060

Kawagoe, Saitama, Japan

JP00161

Kawagoe, Saitama, Japan

JP00062

Kawaguchi, Saitama, Japan

JP00052

Sayama, Saitama, Japan

JP00008

Tokorozawa, Saitama, Japan

JP00133

Kakegawa, Shizuoka, Japan

JP00077

Kanuma, Tochigi, Japan

JP00024

Bunkyo, Tokyo, Japan

JP00043

Bunkyo, Tokyo, Japan

JP00149

Bunkyo, Tokyo, Japan

JP00152

Bunkyo, Tokyo, Japan

JP00095

Chiyoda, Tokyo, Japan

JP00099

Chiyoda, Tokyo, Japan

JP00142

Chuo, Tokyo, Japan

JP00063

Hachioji, Tokyo, Japan

JP00053

Kiyose, Tokyo, Japan

JP00072

Meguro, Tokyo, Japan

JP00083

Meguro, Tokyo, Japan

JP00148

Ota, Tokyo, Japan

JP00100

Setagaya, Tokyo, Japan

JP00032

Shinjuku, Tokyo, Japan

JP00010

Takaoka, Toyama, Japan

JP00155

Nishimuro, Wakayama, Japan

JP00104

Shimonoseki, Yamaguchi, Japan

JP00047

Shunan, Yamaguchi, Japan

JP00018

Fukuoka, Japan

JP00020

Fukuoka, Japan

JP00035

Fukuoka, Japan

JP00059

Fukuoka, Japan

JP00067

Fukuoka, Japan

JP00076

Fukuoka, Japan

JP00131

Fukuoka, Japan

JP00164

Fukuoka, Japan

JP00013

Hiroshima, Japan

JP00014

Hiroshima, Japan

JP00015

Hiroshima, Japan

JP00016

Hiroshima, Japan

JP00055

Hiroshima, Japan

JP00065

Kagoshima, Japan

JP00074

Kagoshima, Japan

JP00093

Kochi, Japan

JP00022

Kumamoto, Japan

JP00046

Kumamoto, Japan

JP00123

Kyoto, Japan

JP00159

Kyoto, Japan

JP00023

Miyagi, Japan

JP00122

Miyazaki, Japan

JP00080

Nagano, Japan

JP00098

Nagasaki, Japan

JP00112

Nagasaki, Japan

JP00147

Nagasaki, Japan

JP00017

Oita, Japan

JP00118

Okayama, Japan

JP00150

Osaka, Japan

JP00157

Osaka, Japan

JP00089

Shizuoka, Japan

JP00135

Shizuoka, Japan

JP00139

Toyama, Japan

Korea, Republic of

KR00504

Daegu, Korea, Republic of

KR00510

Daegu, Korea, Republic of

KR00505

Gwangju, Korea, Republic of

KR00506

Incheon, Korea, Republic of

KR00508

Jeonju, Korea, Republic of

KR00501

Seoul, Korea, Republic of

KR00502

Seoul, Korea, Republic of

KR00503

Seoul, Korea, Republic of

KR00509

Seoul, Korea, Republic of

KR00511

Seoul, Korea, Republic of

KR00507

Suwon, Korea, Republic of

Taiwan

TW00708

Kaohsiung, Taiwan

TW00709

Kaohsiung, Taiwan

TW00704

Taichung, Taiwan

TW00705

Taichung, Taiwan

TW00710

Taichung, Taiwan

TW00712

Tainan, Taiwan

TW00701

Taipei, Taiwan

TW00702

Taipei, Taiwan

TW00711

Taipei, Taiwan

TW00703

Taoyuan, Taiwan

Sponsors and Collaborators

Astellas Pharma Inc

Investigators

• Study Director: Medical Director; Astellas Pharma Inc

  Study Documents (Full-Text)

Documents provided by Astellas Pharma Inc:

Study Protocol  [PDF] March 3, 2017

Statistical Analysis Plan  [PDF] January 19, 2018

More Information

Additional Information:

Link to results on Astellas Clinical Study Results website 

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Tanaka Y, Takeuchi T, Izutsu H, Kaneko Y, Kato D, Fukuda M, Rokuda M, Schultz NM. Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis. Arthritis Res Ther. 2021 Aug 24;23(1):221. doi: 10.1186/s13075-021-02590-z.

Toyoshima J, Kaibara A, Shibata M, Kaneko Y, Izutsu H, Nishimura T. Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis. Pharmacol Res Perspect. 2021 May;9(3):e00744. doi: 10.1002/prp2.744.

Toyoshima J, Shibata M, Kaibara A, Kaneko Y, Izutsu H, Nishimura T. Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis. Br J Clin Pharmacol. 2021 Apr;87(4):2014-2022. doi: 10.1111/bcp.14605. Epub 2020 Dec 1.

Tanaka Y, Takeuchi T, Tanaka S, Kawakami A, Iwasaki M, Song YW, Chen YH, Wei JC, Lee SH, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Akazawa R, Shiomi T, Yamada E. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis. 2019 Oct;78(10):1320-1332. doi: 10.1136/annrheumdis-2019-215163. Epub 2019 Jul 26.

• Responsible Party: Astellas Pharma Inc
• ClinicalTrials.gov Identifier: NCT02308163
• Other Study ID Numbers: 015K-CL-RAJ3
• First Posted: December 4, 2014
• Results First Posted: March 16, 2020
• Last Update Posted: March 16, 2020
• Last Verified: February 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP); Clinical Study Report (CSR)
• Time Frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
• Access Criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
• URL: https://www.clinicalstudydatarequest.com/

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Astellas Pharma Inc:

Rheumatoid Arthritis; ASP015K

Additional relevant MeSH terms:

Arthritis; Arthritis, Rheumatoid; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Etanercept; Peficitinib; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Anti-Inflammatory Agents; Antirheumatic Agents; Gastrointestinal Agents; Immunosuppressive Agents; Immunologic Factors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action